rabeprazole has been researched along with Indigestion in 38 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although there was no significant difference between placebo and rabeprazole groups in complete symptom relief for four major dyspeptic symptoms, the satisfactory symptom relief of rabeprazole 20 mg was significantly higher than placebo according to the dyspepsia symptom questionnaire (45." | 9.17 | Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. ( Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Hiraishi, H; Hongo, M; Inamori, M; Iwakiri, K; Iwakiri, R; Kanke, K; Kato, M; Kinoshita, Y; Kusano, M; Masuyama, H; Miwa, H; Nagahara, A; Naito, Y; Takahashi, S; Tominaga, K; Watanabe, S, 2013) |
| "Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients." | 9.14 | Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. ( Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM, 2010) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 9.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 7.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "The total symptom score of Nepean Dyspepsia Index-Korean decreased in the rabeprazole single group (29." | 5.41 | Multicenter, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Controlled-release, Once-daily UIC201609/UIC201610 Combination Therapy for Functional Dyspepsia: Preliminary Study. ( Choi, SC; Kim, N; Lee, JW; Lee, KJ; Youn, YH, 2021) |
| "Acute interstitial nephritis is an uncommon but important cause of acute renal failure." | 5.33 | Rabeprazole-induced acute interstitial nephritis. ( Coleman, PL; Geevasinga, N; Roger, SD, 2005) |
| "The aim of this study is to clarify whether acotiamide and rabeprazole combination therapy can improve clinical symptoms, gastric emptying, and satisfaction with treatment in functional dyspepsia (FD) patients more effectively than acotiamide or rabeprazole monotherapy alone." | 5.22 | Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. ( Akamizu, T; Futagami, S; Gudis, K; Hashimoto, S; Iwakiri, K; Kawagoe, T; Kodaka, Y; Maruki, Y; Nagoya, H; Sakamoto, C; Sato, H; Yamawaki, H, 2016) |
| " Although there was no significant difference between placebo and rabeprazole groups in complete symptom relief for four major dyspeptic symptoms, the satisfactory symptom relief of rabeprazole 20 mg was significantly higher than placebo according to the dyspepsia symptom questionnaire (45." | 5.17 | Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. ( Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Hiraishi, H; Hongo, M; Inamori, M; Iwakiri, K; Iwakiri, R; Kanke, K; Kato, M; Kinoshita, Y; Kusano, M; Masuyama, H; Miwa, H; Nagahara, A; Naito, Y; Takahashi, S; Tominaga, K; Watanabe, S, 2013) |
| "The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22." | 5.16 | Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. ( Amemoto, K; Ashida, K; Esaki, H; Fukuchi, T; Hashimoto, T; Isowa, G; Kiyota, K; Majima, K; Morikawa, H; Murotani, M; Ohyama, Y; Oka, H; Sakaguchi, M; Takao, F; Takao, M; Yamashita, H, 2012) |
| "Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients." | 5.14 | Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. ( Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM, 2010) |
| "The aim of the study was to evaluate and document the efficacy and tolerability of rabeto plus (FDC of rabeprazole and itopride) in management of functional dyspepsia." | 5.13 | Rabeto plus: a valuable drug for managing functional dyspepsia. ( Basu, M; Dabholkar, P; Ghosh, A; Halder, S; Mandal, A; Mandal, S, 2008) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 5.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "The aims of the study are to clarify the pathophysiological differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way." | 3.91 | Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. ( Agawa, S; Futagami, S; Gudis, K; Higuchi, K; Iwakiri, K; Kaneko, K; Kawamoto, C; Kodaka, Y; Murakami, M; Sakasegawa, N; Ueki, N; Wakabayashi, M; Yamawaki, H, 2019) |
| "We administered rabeprazole 10 mg for 4 weeks to NERD/FD patients, who also answered a modified version of the Frequency Scale for Symptoms of gastroesophageal reflux disease (GERD) (FSSG), which added a pain score to the FSSG." | 3.81 | Pretreatment prediction of symptom response to proton pump inhibitor therapy. ( Asaoka, D; Hojo, M; Matsumoto, K; Miwa, H; Nagahara, A; Osada, T; Sasaki, H; Shimada, Y; Watanabe, S, 2015) |
| "Patients with uninvestigated dyspepsia (n = 104; male/female 41/63) were treated with either rabeprazole 10 mg o." | 3.76 | Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia. ( Asaoka, D; Hojo, M; Ishikawa, D; Kawabe, M; Nagahara, A; Oguro, M; Osada, T; Otaka, M; Shimada, Y; Watanabe, S; Yoshizawa, T, 2010) |
| "Proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) leads to a clinical decline in the quality of life (QOL)." | 2.90 | Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. ( Harada, S; Higuchi, K; Hongo, H; Inoue, T; Kimura, T; Kojima, Y; Murano, M; Noguchi, T; Ota, K; Takeuchi, N; Takeuchi, T, 2019) |
| "Gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) often coexist or overlap." | 2.87 | Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. ( Harada, S; Higashino, T; Higuchi, K; Hoshimoto, M; Itabashi, T; Kawaguchi, S; Kojima, K; Kojima, Y; Kuramoto, T; Kusano, M; Ota, K; Sakaguchi, M; Sakamoto, H; Sanomura, M; Takada, K; Takahashi, Y; Takeuchi, T; Tominaga, K, 2018) |
| "A new questionnaire for assessing gastroesophageal reflux disease (GERD), the Frequency Scale for Symptoms of GERD, covers the 12 most common symptoms of GERD patients." | 2.73 | Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. ( Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H, 2007) |
| "Rabeprazole treatment reduced aggregate postprandial symptoms, particularly fullness, 30 min after the meal (P = 0." | 2.72 | Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. ( Burton, DD; Camilleri, M; Grudell, AB; Stephens, DA, 2006) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Rabeprazole was the most frequently used PPI (2467/3739, 66." | 1.91 | Dyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study). ( Bhagat, S; Desai, SA; Kotak, B; Mane, A; Pebbili, KK; Rathod, R; Sud, R, 2023) |
| "Acute interstitial nephritis is an uncommon but important cause of acute renal failure." | 1.33 | Rabeprazole-induced acute interstitial nephritis. ( Coleman, PL; Geevasinga, N; Roger, SD, 2005) |
| "pylori in children with type 1 diabetes mellitus improves their metabolic control." | 1.32 | Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. ( Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 15 (39.47) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Sud, R | 1 |
| Pebbili, KK | 1 |
| Desai, SA | 1 |
| Bhagat, S | 1 |
| Rathod, R | 1 |
| Mane, A | 1 |
| Kotak, B | 1 |
| Lee, JW | 1 |
| Youn, YH | 1 |
| Choi, SC | 1 |
| Lee, KJ | 1 |
| Kim, N | 1 |
| Takeuchi, T | 2 |
| Takahashi, Y | 1 |
| Kawaguchi, S | 1 |
| Ota, K | 2 |
| Harada, S | 2 |
| Kojima, Y | 2 |
| Sakamoto, H | 1 |
| Kuramoto, T | 1 |
| Kojima, K | 1 |
| Sanomura, M | 1 |
| Hoshimoto, M | 1 |
| Higashino, T | 1 |
| Itabashi, T | 1 |
| Takada, K | 1 |
| Sakaguchi, M | 2 |
| Tominaga, K | 2 |
| Kusano, M | 3 |
| Higuchi, K | 4 |
| Yamawaki, H | 2 |
| Futagami, S | 2 |
| Kaneko, K | 1 |
| Agawa, S | 1 |
| Murakami, M | 1 |
| Wakabayashi, M | 1 |
| Sakasegawa, N | 1 |
| Kodaka, Y | 2 |
| Ueki, N | 1 |
| Gudis, K | 2 |
| Kawamoto, C | 1 |
| Iwakiri, K | 3 |
| Hongo, H | 1 |
| Kimura, T | 1 |
| Takeuchi, N | 1 |
| Noguchi, T | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Iwakiri, R | 2 |
| Furuta, K | 1 |
| Inamori, M | 1 |
| Furuta, T | 1 |
| Masuyama, H | 1 |
| Kanke, K | 1 |
| Nagahara, A | 4 |
| Haruma, K | 1 |
| Kinoshita, Y | 1 |
| Takahashi, S | 1 |
| Kato, M | 1 |
| Hongo, M | 1 |
| Hiraishi, H | 1 |
| Watanabe, S | 3 |
| Miwa, H | 3 |
| Naito, Y | 1 |
| Fujimoto, K | 1 |
| Arakawa, T | 1 |
| Yap, PR | 1 |
| Mahadeva, S | 1 |
| Goh, KL | 1 |
| Asaoka, D | 2 |
| Shimada, Y | 2 |
| Sasaki, H | 1 |
| Matsumoto, K | 1 |
| Osada, T | 2 |
| Hojo, M | 3 |
| Kawagoe, T | 1 |
| Maruki, Y | 1 |
| Hashimoto, S | 1 |
| Nagoya, H | 1 |
| Sato, H | 1 |
| Akamizu, T | 1 |
| Sakamoto, C | 1 |
| de Artaza Varasa, T | 1 |
| Valle Muñoz, J | 1 |
| Pérez-Grueso, MJ | 1 |
| García Vela, A | 1 |
| Martín Escobedo, R | 1 |
| Rodríguez Merlo, R | 1 |
| Cuena Boy, R | 1 |
| Carrobles Jiménez, JM | 1 |
| Hong, EJ | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Song, MJ | 1 |
| Choi, WH | 1 |
| Hong, CH | 1 |
| Park, JH | 1 |
| Kim, HJ | 1 |
| Cho, YK | 1 |
| Shon, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Pellicano, R | 1 |
| Ghosh, A | 1 |
| Halder, S | 1 |
| Mandal, S | 1 |
| Mandal, A | 1 |
| Basu, M | 1 |
| Dabholkar, P | 1 |
| Oguro, M | 1 |
| Ishikawa, D | 1 |
| Kawabe, M | 1 |
| Yoshizawa, T | 1 |
| Otaka, M | 1 |
| Xiao, YL | 1 |
| Peng, S | 1 |
| Tao, J | 1 |
| Wang, AJ | 1 |
| Lin, JK | 1 |
| Hu, PJ | 1 |
| Chen, MH | 1 |
| Lee, VW | 1 |
| Chau, TS | 1 |
| Chan, AK | 1 |
| Lee, KK | 1 |
| Waye, MM | 1 |
| Ling, TK | 1 |
| Chan, FK | 1 |
| Stanghellini, V | 1 |
| Frisoni, C | 1 |
| Savarino, E | 1 |
| Zentilin, P | 2 |
| Dulbecco, P | 2 |
| Malesci, A | 1 |
| Savarino, V | 2 |
| Takao, M | 1 |
| Ohyama, Y | 1 |
| Oka, H | 1 |
| Yamashita, H | 1 |
| Fukuchi, T | 1 |
| Ashida, K | 1 |
| Murotani, M | 2 |
| Majima, K | 1 |
| Morikawa, H | 1 |
| Hashimoto, T | 1 |
| Kiyota, K | 1 |
| Esaki, H | 1 |
| Amemoto, K | 1 |
| Isowa, G | 1 |
| Takao, F | 1 |
| Zhao, S | 1 |
| Sha, H | 1 |
| Li, ZY | 1 |
| Ren, CS | 1 |
| De Francesco, V | 5 |
| Faleo, D | 2 |
| Panella, C | 4 |
| Ierardi, E | 5 |
| Margiotta, M | 2 |
| Murakami, K | 1 |
| Sato, R | 1 |
| Okimoto, T | 1 |
| Nasu, M | 1 |
| Fujioka, T | 1 |
| Kodama, M | 1 |
| Kagawa, J | 1 |
| Zullo, A | 3 |
| Vaira, D | 1 |
| Vakil, N | 1 |
| Hassan, C | 2 |
| Gatta, L | 1 |
| Ricci, C | 1 |
| Menegatti, M | 1 |
| Tampieri, A | 1 |
| Perna, F | 1 |
| Rinaldi, V | 1 |
| Perri, F | 1 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 1 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 1 |
| Miglioli, M | 1 |
| Morini, S | 3 |
| Santarelli, L | 1 |
| Gabrielli, M | 1 |
| Candelli, M | 2 |
| Cremonini, F | 1 |
| Nista, EC | 2 |
| Cammarota, G | 2 |
| Gasbarrini, G | 2 |
| Gasbarrini, A | 2 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Iiritano, E | 1 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Di Leo, A | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 3 |
| Francavilla, A | 1 |
| Rigante, D | 1 |
| Marietti, G | 1 |
| Crea, F | 1 |
| Schiavino, A | 1 |
| Pignataro, G | 1 |
| Petrucci, S | 1 |
| Della Valle, N | 2 |
| Amoruso, A | 1 |
| Muscatiello, N | 1 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 1 |
| Garza-González, E | 1 |
| Tijerina-Menchaca, R | 1 |
| Pérez-Pérez, GI | 1 |
| Bosques-Padilla, FJ | 1 |
| Geevasinga, N | 1 |
| Coleman, PL | 1 |
| Roger, SD | 1 |
| Wong, WM | 1 |
| Huang, J | 1 |
| Xia, HH | 1 |
| Fung, FM | 1 |
| Tong, TS | 1 |
| Cheung, KL | 1 |
| Ho, VY | 1 |
| Lai, KC | 1 |
| Chan, CK | 1 |
| Chan, AO | 1 |
| Hui, CK | 1 |
| Lam, SK | 1 |
| Wong, BC | 1 |
| Calvet, X | 1 |
| Ducons, J | 1 |
| Bujanda, L | 1 |
| Bory, F | 1 |
| Montserrat, A | 1 |
| Gisbert, JP | 1 |
| Grudell, AB | 1 |
| Camilleri, M | 1 |
| Burton, DD | 1 |
| Stephens, DA | 1 |
| Shimoyama, Y | 1 |
| Kawamura, O | 1 |
| Maeda, M | 1 |
| Kuribayashi, S | 1 |
| Nagoshi, A | 1 |
| Zai, H | 1 |
| Moki, F | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Sugimoto, S | 1 |
| Mori, M | 1 |
| Ohkura, R | 1 |
| Yamada, T | 1 |
| Sato, K | 1 |
| Sato, N | 1 |
| Ivanova, NG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia[NCT01089543] | Phase 2 | 338 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants. (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| DSQ (n= 76, n= 75, n= 74, n= 78) | Diary Recordings (n= 77, n= 76, n=74, n=80) | |
| Placebo | 17.9 | 17.5 |
| Rabeprazole 10 mg | 22.4 | 22.1 |
| Rabeprazole 20 mg | 29.3 | 28.9 |
| Rabeprazole 40 mg | 27.0 | 27.0 |
"The rate of satisfactory symptom relief according to the DSQ defined as scores of <= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of <= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered yes or no when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants." (NCT01089543)
Timeframe: Up to 8 Weeks (including 7 days prior)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| DSQ (n=76, n=75, n=74, n=78) | Diary Recordings (n=77, n=76, n=74, n=80) | Treatment Success (n=76, n=75, n=74, n=78) | |
| Placebo | 28.2 | 30.0 | 59.0 |
| Rabeprazole 10 mg | 42.1 | 37.7 | 72.4 |
| Rabeprazole 20 mg | 45.3 | 48.7 | 85.3 |
| Rabeprazole 40 mg | 39.2 | 39.2 | 64.9 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
1 review available for rabeprazole and Indigestion
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
21 trials available for rabeprazole and Indigestion
| Article | Year |
|---|---|
Multicenter, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Controlled-release, Once-daily UIC201609/UIC201610 Combination Therapy for Functional Dyspepsia: Preliminary Study.
Topics: Delayed-Action Preparations; Dyspepsia; Gastrointestinal Agents; Humans; Rabeprazole; Treatment Outc | 2021 |
Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 2018 |
Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Topics: Adult; Aged; Drug Therapy, Combination; Drugs, Chinese Herbal; Dyspepsia; Female; Gastroesophageal R | 2019 |
Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Topics: Double-Blind Method; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pyl | 2013 |
Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
Topics: Abdominal Pain; Acylation; Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Drug | 2016 |
[Effect of Helicobacter pylori eradication on patients with functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Rabeto plus: a valuable drug for managing functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzamides; Benzyl Compounds; Drug | 2008 |
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2010 |
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzamides; Dyspepsia; Esop | 2012 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzi | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Dyspepsia; Enzyme Inhibitors; F | 2006 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Hu | 2007 |
[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Benzimidazoles; Dyspepsia; Enzyme Inhibi | 2002 |
16 other studies available for rabeprazole and Indigestion
| Article | Year |
|---|---|
Dyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study).
Topics: Adolescent; Adult; Cross-Sectional Studies; Demography; Dyspepsia; Female; Humans; India; Male; Midd | 2023 |
Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities.
Topics: Abdominal Pain; Aged; Benzamides; Drug Therapy, Combination; Dyspepsia; Esters; Female; Gabexate; Ga | 2019 |
Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.
Topics: Dyspepsia; Female; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors; Rabeprazole | 2013 |
Commentary: rabeprazole improves symptoms in patients with functional dyspepsia in Japan - author's reply.
Topics: Dyspepsia; Female; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors; Rabeprazole | 2013 |
Pretreatment prediction of symptom response to proton pump inhibitor therapy.
Topics: Adult; Aged; Dyspepsia; Female; Forecasting; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pro | 2015 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Dyspepsia; Esophageal Motility Disorders | 2010 |
Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chi-Square Distribution; Dyspepsia | 2010 |
Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophageal pH Monitoring; Esophagoscopy; Gastroe | 2010 |
The role of Acid in functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2011 |
Electrical bioimpedance gastric motility measurement based on an electrical-mechanical composite mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Case-Control Studies; China; Domperidone; Dopamine A | 2012 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2004 |
Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
Rabeprazole-induced acute interstitial nephritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Acute Kidney Injury; Anti-Ulcer Agents; Benz | 2005 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |